Long-term assessment of striatal dopamine transporters in parkinsonian patients with intrastriatal embryonic mesencephalic grafts

  • Oliver Pogarell
  • Walter Koch
  • Franz J. Gildehaus
  • Andreas Kupsch
  • Olle Lindvall
  • Wolfgang H. Oertel
  • Klaus Tatsch
Original article



Single-photon emission computed tomography (SPECT) of striatal dopamine transporters (DAT) has been used to demonstrate presynaptic dopaminergic dysfunction and to monitor the progression of Parkinson’s disease. In parkinsonian patients who were implanted with embryonic mesencephalic tissue in the striatum, positron emission tomography (PET) has shown an increase in striatal [18F]dopa uptake as an indicator of graft survival and striatal reinnervation. The aim of this study was to investigate two patients who had undergone bilateral intrastriatal transplantation of human embryonic mesencephalic tissue using SPECT and the 123I-labelled DAT ligand N-(3-iodopropen-2-yl)-2β-carbomethoxy-3β-(4-chlorophenyl) tropane (IPT).


Two patients were subjected to [123I]IPT SPECT according to a standardised protocol prospectively and repeatedly up to 8 years after transplantation.


From baseline to year 3 after transplantation, mean striatal DAT availability increased by a mean of 61% (93% and 29% in patients 1 and 2, respectively). It then remained relatively stable up to 8 years in patient 2, but increased further by another 77% of baseline values in patient 1. Clinically, both patients experienced a moderate improvement in motor performance but developed moderate (patient 2) to severe (patient 1) off-medication dyskinesias.


Our data indicate that DAT imaging using IPT and SPECT can be used to demonstrate graft survival following dopaminergic tissue implantation. Because SPECT with DAT ligands is widely available in the routine clinical setting, this methodology may be a useful alternative to [18F]dopa PET for repeated scanning of grafted parkinsonian patients. The relevance of the long-term increase in DAT binding for the development of off-medication dyskinesias remains to be elucidated further.


Parkinson’s disease Striatal grafts SPECT Dopamine transporter 


  1. 1.
    Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71–6PubMedCrossRefGoogle Scholar
  2. 2.
    Oertel WH, Quinn, N. Parkinsonism. In: Brandt T, Diener HC, Caplan LR, eds. Neurological disorders: course and treatment. San Diego, CA: Academic Press; 1996; p. 715–72Google Scholar
  3. 3.
    Lang AE, Lozano AM. Parkinson’s disease. Second of two parts. N Engl J Med 1998;339:1130–43PubMedCrossRefGoogle Scholar
  4. 4.
    Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N Engl J Med 1998;339:1044–53PubMedCrossRefGoogle Scholar
  5. 5.
    Annett L. Functional studies of neural grafts in parkinsonian primates. In: Dunnett SB, Björklund A, eds. Functional neural transplantation. New York: Raven Press; 1994; p. 71–102Google Scholar
  6. 6.
    Brundin P, Duan WM, Sauer H. Functional effects of mesencephalic dopamine neurons and adrenal chromaffin cells grafted to the rodent striatum. In: Dunnett SB, Björklund A, eds. Functional neural transplantation. New York: Raven Press; 1994; p. 9–46Google Scholar
  7. 7.
    Lindvall O, Hagell P. Clinical observations after neural transplantation in Parkinson’s disease. Prog Brain Res 2000;127:299–320PubMedCrossRefGoogle Scholar
  8. 8.
    Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 2001;344:710–9PubMedCrossRefGoogle Scholar
  9. 9.
    Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 2003;54:403–14PubMedCrossRefGoogle Scholar
  10. 10.
    Polgar S, Morris ME, Reilly S, Bilney B, Sanberg PR. Reconstructive neurosurgery for Parkinson’s disease: a systematic review and preliminary meta-analysis. Brain Res Bull 2003;60:1–24PubMedCrossRefGoogle Scholar
  11. 11.
    Hagell P, Piccini P, Bjorklund A, Brundin P, Rehncrona S, Widner H, et al. Dyskinesias following neural transplantation in Parkinson’s disease. Nat Neurosci 2002;5:627–8PubMedGoogle Scholar
  12. 12.
    Brooks DJ. Monitoring neuroprotection and restorative therapies in Parkinson’s disease with PET. J Neural Transm Suppl 2000;60:125–37PubMedGoogle Scholar
  13. 13.
    Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson’s disease. Brain 2000;123(Pt 7):1380–90PubMedCrossRefGoogle Scholar
  14. 14.
    Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJ, Mufson EJ, Sanberg PR, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. N Engl J Med 1995;332:1118–24PubMedCrossRefGoogle Scholar
  15. 15.
    Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J. Striatal dopamine transporter binding in early to moderately advanced Parkinson’s disease: monitoring of disease progression over 2 years. Nucl Med Commun 2001;22:721–5PubMedCrossRefGoogle Scholar
  16. 16.
    Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, et al. Relationship between clinical features of Parkinson’s disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography. Eur J Nucl Med 1997;24:415–21PubMedGoogle Scholar
  17. 17.
    Brucke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wober C, et al. Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I]beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997;50:9–24PubMedGoogle Scholar
  18. 18.
    Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A. 1993;90:11965–9PubMedCrossRefGoogle Scholar
  19. 19.
    Schwarz J, Storch A, Koch W, Pogarell O, Radau PE, Tatsch K. Loss of dopamine transporter binding in Parkinson’s disease follows a single exponential rather than linear decline. J Nucl Med 2004;45:1694–7PubMedGoogle Scholar
  20. 20.
    Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology 2001;57:2089–94PubMedGoogle Scholar
  21. 21.
    Pirker W, Holler I, Gerschlager W, Asenbaum S, Zettinig G, Brucke T. Measuring the rate of progression of Parkinson’s disease over a 5-year period with beta-CIT SPECT. Mov Disord 2003;18:1266–72PubMedCrossRefGoogle Scholar
  22. 22.
    Seibyl J, Jennings D, Tabamo R, Marek K. Neuroimaging trials of Parkinson’s disease progression. J Neurol 2004;251 Suppl 7:vII9–13PubMedCrossRefGoogle Scholar
  23. 23.
    Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, Wolters EC. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson’s disease. J Neural Transm 2001;108:1011–9PubMedCrossRefGoogle Scholar
  24. 24.
    Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P, et al. Rate of progression in Parkinson’s disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 2001;16:608–15PubMedCrossRefGoogle Scholar
  25. 25.
    Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314–9PubMedCrossRefGoogle Scholar
  26. 26.
    Lindvall O, Rehncrona S, Brundin P, Gustavii B, Astedt B, Widner H, et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson’s disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 1989;46:615–31PubMedGoogle Scholar
  27. 27.
    Rehncrona S. A critical review of the current status and possible developments in brain transplantation. Adv Tech Stand Neurosurg 1997;23:3–46PubMedGoogle Scholar
  28. 28.
    Fahn S, Elton RL. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson’s disease. Florham Park, NJ: Macmillan Health Care Information; 1987; p. 153–64Google Scholar
  29. 29.
    Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992;7:2–13PubMedCrossRefGoogle Scholar
  30. 30.
    Kordower JH, Freeman TB, Chen EY, Mufson EJ, Sanberg PR, Hauser RA, et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson’s disease. Mov Disord 1998;13:383–93PubMedCrossRefGoogle Scholar
  31. 31.
    Sperfeld AD, Collatz MB, Baier H, Palmbach M, Storch A, Schwarz J, et al. FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann Neurol 1999;46:708–15PubMedCrossRefGoogle Scholar
  32. 32.
    Linke R, Gostomzyk J, Hahn K, Tatsch K. [123I]IPT binding to the presynaptic dopamine transporter: variation of intra- and interobserver data evaluation in parkinsonian patients and controls. Eur J Nucl Med 2000;27:1809–12PubMedCrossRefGoogle Scholar
  33. 33.
    Thobois S, Jahanshahi M, Pinto S, Frackowiak R, Limousin-Dowsey P. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences. Neuroimage 2004;23:1–16PubMedCrossRefGoogle Scholar
  34. 34.
    Remy P, Samson Y, Hantraye P, Fontaine A, Defer G, Mangin JF, et al. Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol 1995;38:580–8PubMedCrossRefGoogle Scholar
  35. 35.
    Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 1999;56:179–87PubMedCrossRefGoogle Scholar
  36. 36.
    Ma Y, Feigin A, Dhawan V, Fukuda M, Shi Q, Greene P, et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 2002;52:628–34PubMedCrossRefGoogle Scholar
  37. 37.
    Piccini P, Brooks DJ, Bjorklund A, Gunn RN, Grasby PM, Rimoldi O, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson’s patient. Nat Neurosci 1999;2:1137–40PubMedCrossRefGoogle Scholar
  38. 38.
    Piccini P, Lindvall O, Bjorklund A, Brundin P, Hagell P, Ceravolo R, et al. Delayed recovery of movement-related cortical function in Parkinson’s disease after striatal dopaminergic grafts. Ann Neurol 2000;48:689–95PubMedCrossRefGoogle Scholar
  39. 39.
    Piccini P. Dyskinesias after transplantation in Parkinson’s disease. Lancet Neurol 2002;1:472PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Oliver Pogarell
    • 1
    • 5
  • Walter Koch
    • 2
  • Franz J. Gildehaus
    • 2
  • Andreas Kupsch
    • 3
  • Olle Lindvall
    • 4
  • Wolfgang H. Oertel
    • 5
  • Klaus Tatsch
    • 2
  1. 1.Department of PsychiatryLudwig Maximilians UniversityMunichGermany
  2. 2.Department of Nuclear Medicine, Klinikum GrosshadernLudwig Maximilians UniversityMunichGermany
  3. 3.Department of NeurologyCharité, Humboldt UniversityBerlinGermany
  4. 4.Section of Restorative NeurologyWallenberg Neuroscience CentreLundSweden
  5. 5.Department of NeurologyPhilipps UniversityMarburgGermany

Personalised recommendations